Press Releases

Year

Sep 25 2018

Intec Pharma to Present Multiple Posters at International Congress of Parkinson's and Movement Disorder Society

JERUSALEM , Sept. 25, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that three posters in support of the Company's Phase 3 clinical development program for the Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD), will be presented at the upcoming

Sep 20 2018

Intec Pharma to Participate at Upcoming Investment Conferences

JERUSALEM , Sept. 20, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that Company management will participate at the following upcoming investment conferences. Oppenheimer 2018 Fall Summit - Focused on Specialty Pharma and Rare Disease Date:

Aug 15 2018

Intec Pharma Reports Second Quarter 2018 Financial Results and Corporate Update

Enrolled more than 95% of patients in pivotal Phase 3 ACCORDANCE trial and more than 85% of eligible patients entered the open label extension study JERUSALEM , Aug. 15, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces financial results for the

Jun 29 2018

Intec Pharma Appoints William Bradley Hayes to Board of Directors

Former LabCorp CFO Brings Wealth of Financial Experience JERUSALEM, June 29, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: NTEC) ("Intec" or "the Company") today announces the appointment of William Bradley Hayes (Brad) to the Company's Board of Directors. Mr.

May 31 2018

Intec Pharma to Present at Jefferies 2018 Healthcare Conference

JERUSALEM , May 31, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NETC) (TASE: NTEC) (" Intec " or "the Company") today announces that Company management will participate at the upcoming Jefferies 2018 Healthcare Conference taking place June 5 - 8, 2018 in New York City . Jeffrey A.

May 15 2018

Intec Pharma Reports First Quarter 2018 Financial Results and Corporate Update

More than 350 patients enrolled in pivotal Phase 3 ACCORDANCE trial and more than 80% of eligible patients entered the open label extension study JERUSALEM , May 15, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: NTEC) (" Intec " or "the Company") today announces financial results for

Apr 24 2018

Intec Pharma Presented Phase 1 PK and Safety Data From Accordion Pill Carbidopa/Levodopa at American Academy of Neurology Annual Meeting

JERUSALEM, April 24, 2018 /PRNewswire/ -- Intec Pharma LTD (NASDAQ, TASE:NTEC) ("Intec" or "the Company") today announces that data collected from two Phase 1 studies of its proprietary Accordion Pill Carbidopa/Levodopa (AP-CD/LD) for Parkinson's disease were highlighted in a poster presentation at

Apr 13 2018

Intec Pharma Announces Closing of $35.4 Million Public Offering of Ordinary Shares

Intec Pharma Announces Closing of $35.4 Million Public Offering of Ordinary Shares JERUSALEM, April 13, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced the closing of its previously announced offering of 6.75 million of its ordinary shares, at a public offering price

Apr 11 2018

Intec Pharma Announces Pricing of $35.4 Million Public Offering of Ordinary Shares

JERUSALEM, April 11, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced the pricing of an underwritten public offering of 6.75 million of its ordinary shares at a public offering price of $5.25 per ordinary share. The gross proceeds of the offering are expected to be

Apr 10 2018

Intec Pharma Announces Proposed Public Offering of Ordinary Shares

JERUSALEM, April 10, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: NTEC) today announced the launch of an underwritten public offering of its ordinary shares. In connection with this offering, Intec Pharma also intends to grant the underwriters a 30-day option to purchase up to an

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
Next page
Last page

Displaying 11 - 20 of 81